CoChat

Dual gut hormone receptor agonists for diabetes and obesity

Open access
Bass, Joseph, Tschöp, Matthias H., Beutler, Lisa R. · 2023 · Journal of Clinical Investigation

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Introduction The epidemics of obesity and type 2 diabetes mellitus (T2DM) pose enormous threats to human health. Weight loss of at least 5%–10% attenuates the severity of these disorders and their complications. Diet and lifestyle modification are necessary but not sufficient for sustained weight loss in most people. Historically, antiobesity medications have been modestly effective, with numerous adverse side effects. Bariatric surgery offers sustained weight loss and potential remission of T2DM, but this treatment is impractical for large populations and may be associated with serious surgical and other complications, such as malabsorption and micronutrient deficiencies. The development of analogs of the gut peptide glucagon-like peptide 1 (GLP1) suggested considerable potential for gut hormones for treatment of T2DM and obesity. This culminated with regulatory approval of the GLP1 receptor (GLP1R) agonist semaglutide, which leads to clinically significant weight loss and improves T2DM control in most patients. The discovery of polyagonist drugs that activate multiple gut-brain pathways promises to further transform the management of obesity and T2DM. Recently, the gastric inhibitory polypeptide receptor/GLP1R (GIPR/GLP1R) co-agonist, tirzepatide, became the first polyagonist approved for the treatment of T2DM; it induces a staggering 22% average weight loss in patients with obesity (1). As the development of gut hormone dual-and tri-agonists progresses, there is hope for treatment of obesity and T2DM that rivals the efficacy […]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci167952

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Established and proposed mechanisms underlying the glucoregulatory and weight loss effects of GIP/GLP1R co-agonism.
Figure 1 Established and proposed mechanisms underlying the glucoregulatory and weight loss effects of GIP/GLP1R co-agonism.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 21

Metadata

Authors
Bass, J., Tschöp, M. H., & Beutler, L. R.
Affiliations
  • Northwestern University (US)
  • Helmholtz Munich (DE)
Corresponding author
Beutler, Lisa R.
Venue
Journal of Clinical Investigation
Published
2023-02-01
Volume
133
Issue
3
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4318672182
Cited by
21
References
29
Citations by year
2025: 4 · 2024: 10 · 2023: 7
FWCI
4.31
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK128477, P30DK020595)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, GIP receptor agonist, diabetes mellitus, obesity, incretin-based therapy, gastrointestinal hormones
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hormones, Humans, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.